ATAGI update following weekly COVID-19 meeting – 12 January 2022

Following recent data, ATAGI recommends that severely immunocompromised children between the ages of 5 to 11 years receive a 3rd primary dose of the COVID-19 vaccine to optimise their protection against COVID-19 infection.

Current data has not identified any concerning safety signals in this cohort. ATAGI continues to review and closely monitor reports regarding the safety and efficacy of the COVID-19 vaccine in this age group.

This statement provides a concise summary of the January ATAGI meeting, including the latest recommendations and considerations regarding the safety and efficacy of the COVID-19 vaccine in children ages 5 to 11 years.

To read the full statement, follow the link below:
ATAGI update following weekly COVID-19 meeting - 12 January 2022


ABC: Should I mix or match my booster? Your COVID-19 vaccine questions answered

ATAGI recommends that everyone aged 18 years and over to receive a booster dose of the Pfizer or Moderna COVID-19 vaccine, regardless of which vaccine they received for their primary course.

With over 5 million people now triple jabbed, Australia’s COVID-19 booster rollout is well underway.

This article explores some of the clinical data and considerations regarding the COVID-19 boosters.

To read the full article, follow the link below.
Should I mix or match my booster? Your COVID-19 vaccine questions answered


WHO: 2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022

In 2021, the global health system faced significant challenges perpetuated by the ongoing COVID-19 pandemic. Proving that when health is at risk, everything is at risk. However, there have still been medical breakthroughs and progress including new COVID-19 treatments, the introduction of the world’s first malaria vaccine and the near eradication of polio disease. 

The year 2022 brings a hopeful glimpse to end the COVID-19 pandemic, through countries working together, pushing for greater vaccine equity to reach a 70% global vaccination rate.  

In this article, the WHO reflects on the challenges and triumphs of the global health system throughout 2021 and outlines some positive opportunities for the coming new year. 

To read the full article, follow the link below.  

2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022


CDC: COVID-19 Vaccine Safety in Children Aged 5-11 Years November 3 – December 19 2021

Following the administration of approximately 8 million Pfizer COVID-19 vaccine doses in children between the ages of 5 to 11 years, local and systemic reactions were closely monitored and assessed. The incoming data was reported to VAERS and v-safe, the national passive vaccine safety surveillance system, jointly managed by the CDC and FDA. During the span of 3 November to 19 December, 4,249 reports were submitted, of which 97% were for nonserious adverse events.

For the most recent clinical data regarding the safety and efficacy of the Pfizer COVID-19 vaccine in children aged 5 to 11 years, read the full VAERS report.

COVID-19 Vaccine Safety in Children Aged 5-11 Years November 3 – December 19 2021 

 


European Commission authorises fifth safe and effective vaccine against COVID-19

Nuvaxovid, a COVID-19 vaccine developed by Novavax, has become the fifth COVID-19 vaccine authorised for use in the European Union (EU). Following rigorous safety, efficacy and quality testing by the European Medicines Agency (EMA), the European Commissions has granted a conditional marketing authorization (CMA) of the vaccine for its perceived benefits in providing protection against severe COVID-19 disease. 

 

To read the full statement, follow the link below: 

European Commission authorises fifth safe and effective vaccine against COVID-19

 

 


Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine

Following a routine review examining the safety and efficacy of the Pfizer-BioNTech by the external Independent Data Monitoring Committee (DMC), data has demonstrated that whilst there were no safety concerns,  immunogenicity of a two dose primary course consisting of 3µg doses in the 6 to 24 month-old cohort was met with non-inferiority, but not in the 2 - 5 year old group.

The company has also announced that it will resume studies evaluating a third  3µg dose of COVID-19 vaccine in children 6 months to under 5 years of age in order to select the right dose to maximise the risk-benefit profile in this age group. 

For further information on this study and its findings, follow the link below:  

Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine


The Sydney Morning Herald: Moderna COVID-19 vaccine booster dose ‘appears protective against Omicron’

Following laboratory testing, data shows that whilst a two-dose primary course of the Spikevax (Moderna) vaccine resulted in a low generation of neutralising antibodies against the Omicron variant, a booster dose provided a 37-fold increase in neutralising antibodies. 

 

For more information on these findings refer to the full article via the link below:

Moderna COVID-19 vaccine booster dose ‘appears protective against Omicron’


Raising Children Network - COVID-19 vaccination and children: 5-11 years

Immunising children against COVID-19 ensures stronger, longer-lasting protection than infection does. To build the best immunity, ATAGI recommends that children aged 5 to 11 years should have a 2 dose primary course of the Pfizer COVID-19 vaccine, 8 weeks apart.  

This Raising Children article developed in collaboration with MVEC explores the safety, efficacy and recommendations for immunising children aged 5 to 11 years against COVID-19. 

To read the full article, follow the link below: 

COVID-19 vaccination and children: 5-11 years


Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine

Following recent approval from the TGA, the Australian Technical Advisory Group on Immunisation (ATAGI) have recommended the use of Spikevax (Moderna) as a COVID-19 booster vaccine for people aged 18 years and older (including pregnant women), who have completed their primary course of COVID-19 vaccine 5 or more months ago. The booster dose is half the recommended dose of the Spikevax vaccine used for the primary course. 

ATAGI notes that Moderna and Pfizer COVID-19 vaccines are equally acceptable for use as booster vaccines in Australia in the eligible population.  

To read ATAGI's full statement on the use of the Moderna COVID-19 vaccine as a booster follow the link below:

Australian Technical Advisory Group on Immunisation (ATAGI) recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine


The Conversation: Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine

Most children are fearful of needles and approximately one in five kids (19%) aged 4-6 years old experience needle phobia.

A child’s initial interaction with needles in their primary years may be formative for their relationship with immunisations throughout their lives. As such, it’s important to cultivate a safe and positive vaccination experience.

This article discusses techniques and strategies to help prepare children for vaccination, including accessing professional help from play and child life therapists for those with needle phobia.

To read the full article, please follow the link below:

Is your child frightened of needles? Here’s how to prepare them for their COVID vaccine